[1]
|
Purnell, J.Q. (2000) Definitions, Classification, and Epidemiology of Obesity. MDText.com, Inc., South Dartmouth.
|
[2]
|
Wang, L., Zhou, B., Zhao, Z., Yang, L., Zhang, M., Jiang, Y., et al. (2021) Body-Mass Index and Obesity in Urban and Rural China: Findings from Consecutive Nationally Representative Surveys during 2004-18. Lancet, 398, 53-63.
https://doi.org/10.1016/S0140-6736(21)00798-4
|
[3]
|
张娟, 施小明, 梁晓峰. 2010年中国城乡居民超重和肥胖的直接经济负担分析[J]. 中华流行病学杂志, 2013, 34(6): 598-600.
|
[4]
|
The GBD 2015 Obesity Collaborators (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The New England Journal of Medicine, 377, 13-27. https://doi.org/10.1056/NEJMoa1614362
|
[5]
|
覃潆玉, 刘佳瑞, 郑瑞茂. 肥胖治疗的研究进展[J]. 生理科学进展, 2020, 51(3): 167-173.
|
[6]
|
张书文, 杨德英. 肥胖症药物治疗的研究及评价[J]. 中国保健营养旬刊(下旬刊), 2012, 22(1): 297-298.
|
[7]
|
Greenway, F.L., Aronne, L.J., Raben, A., Astrup, A., Apovian, C.M., Hill, J.O., et al. (2019) A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss. Obesity, 27, 205-216. https://doi.org/10.1002/oby.22347
|
[8]
|
Clément, K., van den Akker, E., Argente, J., Bahm, A., Chung, W.K., Connors, H., et al. (2020) Efficacy and Safety of Setmelanotide, an MC4R Agonist, in Individuals with Severe Obesity Due to LEPR or POMC Deficiency: Single-Arm, Open-Label, Multicentre, Phase 3 Trials. The lancet Diabetes & Endocrinology, 8, 960-970.
https://doi.org/10.1016/S2213-8587(20)30364-8
|
[9]
|
Narayanaswami, V. and Dwoskin, L.P. (2017) Obesity: Current and Potential Pharmacotherapeutics and Targets. Pharmacology & Therapeutics, 170, 116-147. https://doi.org/10.1016/j.pharmthera.2016.10.015
|
[10]
|
Wang, L., Sui, L., Panigrahi, S.K., Meece, K., Xin, Y., Kim, J., et al. (2017) PC1/3 Deficiency Impacts Pro-Opiomelanocortin Processing in Human Embryonic Stem Cell-Derived Hypothalamic Neurons. Stem Cell Reports, 8, 264-277. https://doi.org/10.1016/j.stemcr.2016.12.021
|
[11]
|
Hainer, V., Aldhoon Hainerová, I., Kunešová, M., Taxová Braunerová, R., Zamrazilová, H. and Bendlová, B. (2020) Melanocortin Pathways: Suppressed and Stimulated Melanocortin-4 Receptor (MC4R). Physiological Research, 69, S245-S254. https://doi.org/10.33549/physiolres.934512
|
[12]
|
Sharma, S., Garfield, A.S., Shah, B., Kleyn, P., Ichetovkin, I., Moeller, I.H., et al. (2019) Current Mechanistic and Pharmacodynamic Understanding of Melanocortin-4 Receptor Activation. Molecules, 24, Article No. 1892.
https://doi.org/10.3390/molecules24101892
|
[13]
|
Appel, L., Bergström, M., Buus Lassen, J. and Långström, B. (2014) Tesofensine, a Novel Triple Monoamine Re-Uptake Inhibitor with Anti-Obesity Effects: Dopamine Transporter Occupancy as Measured by PET. European Neuropsychopharmacology, 24, 251-261. https://doi.org/10.1016/j.euroneuro.2013.10.007
|
[14]
|
Recinella, L., Chiavaroli, A., Ferrante, C., Mollica, A., Macedonio, G., Stefanucci, A., et al. (2018) Effects of Central RVD-Hemopressin(α) Administration on Anxiety, Feeding Behavior and Hypothalamic Neuromodulators in the Rat. Pharmacological Reports, 70, 650-657. https://doi.org/10.1016/j.pharep.2018.01.010
|
[15]
|
Astrup, A., Madsbad, S., Breum, L., Jensen, T.J., Kroustrup, J.P. and Meinert Larsen, T. (2008) Effect of Tesofensine on Bodyweight Loss, Body Composition, and Quality of Life in Obese Patients: A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet, 372, 1906-1913. https://doi.org/10.1016/S0140-6736(08)61525-1
|
[16]
|
Shende, P. and Desai, D. (2020) Physiological and Therapeutic Roles of Neuropeptide Y on Biological Functions. In: Turksen, K., Ed., Cell Biology and Translational Medicine, Vol. 7, Vol. 1237, Springer, Cham, 37-47.
https://doi.org/10.1007/5584_2019_427
|
[17]
|
Farhadipour, M. and Depoortere, I. (2021) The Function of Gastrointestinal Hormones in Obesity-Implications for the Regulation of Energy Intake. Nutrients, 13, Article No. 1839. https://doi.org/10.3390/nu13061839
|
[18]
|
Chia, C.W. and Egan, J.M. (2020) Incretins in Obesity and Diabetes. Annals of the New York Academy of Sciences, 1461, 104-126. https://doi.org/10.1111/nyas.14211
|
[19]
|
Bailey, C.J. (2021) Tirzepatide: A New Low for Bodyweight and Blood Glucose. The Lancet Diabetes & Endocrinology, 9, 646-648. https://doi.org/10.1016/S2213-8587(21)00217-5
|
[20]
|
Grudén, S., Forslund, A., Alderborn, G., Söderhäll, A., Hellström, P.M. and Holmbäck, U. (2021) Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. Clinical Pharmacology in Drug Development, 10, 1242-1247. https://doi.org/10.1002/cpdd.920
|
[21]
|
Sugama, J., Moritoh, Y., Yashiro, H., Tsuchimori, K. and Watanabe, M. (2021) Enteropeptidase Inhibition Improves Obesity by Modulating Gut Microbiota Composition and Enterobacterial Metabolites in Diet-Induced Obese Mice. Pharmacological Research, 163, Articlr ID: 105337. https://doi.org/10.1016/j.phrs.2020.105337
|
[22]
|
Rebello, C.J., Zemel, M.B., Kolterman, O., Fleming, G.A. and Greenway, F.L. (2021) Leucine and Sildenafil Combination Therapy Reduces Body Weight and Metformin Enhances the Effect at Low Dose: A Randomized Controlled Trial. American Journal of Therapeutics, 28, e1-e13. https://doi.org/10.1097/MJT.0000000000001303
|
[23]
|
Shin, Y., Lee, D., Ahn, J., Lee, M., Shin, S.S. and Yoon, M. (2021) The Herbal Extract ALS-L1023 from Melissa officinalis Reduces Weight Gain, Elevated Glucose Levels and β-Cell Loss in Otsuka Long-Evans Tokushima Fatty Rats. Journal of Ethnopharmacology, 264, Article ID: 113360. https://doi.org/10.1016/j.jep.2020.113360
|
[24]
|
Woo, S., Yoon, M., Kim, J., Hong, Y., Kim, M.Y., Shin, S.S., et al. (2016) The Anti-Angiogenic Herbal Extract from Melissa officinalis Inhibits Adipogenesis in 3T3-L1 Adipocytes and Suppresses Adipocyte Hypertrophy in High Fat Diet-Induced Obese C57BL/6J Mice. Journal of Ethnopharmacology, 178, 238-250.
https://doi.org/10.1016/j.jep.2015.12.015
|